C¹⁷ Developmental Therapeutics Committee

Under the leadership of Co-chairs Daniel Morgenstern and Chris Maxwell, the C¹⁷ DVL Committee provides greater access across Canada to Phase I/II trials; allowing children and their families an option for investigational treatments while staying closer to home. There are now eleven C¹⁷ centres participating, providing access across Canada for children eligible for these studies.

The C¹⁷ DVL Committee, in partnership with CCTG, opened the first study in September 2010. Several DVL studies have now been funded by C¹⁷ and are either in development, in discussion with pharmaceutical companies, or are identified as potential studies for pediatric oncology based on early adult work.

C¹⁷ DVL Pre-Clinical Studies

The goal is not to wait until pharmaceutical companies want to start clinical trials, as a result of adult data or business decisions, but to actively identify the drugs that have potential efficacy, and develop the capacity to study them in clinical trials. The C¹⁷ DVL Committee is in the process of bridging the gap from bench to bedside with the development of a preclinical program, linking researchers across the country to work together to bring evidence from the lab into clinical studies.

C17 funded grant competitions for DVL pre-clinical research are described on the Research Network Committee page. With funding from C¹⁷, the goal is to quickly identify candidate drugs, the cancer types that might respond, and develop a Phase I clinical trial that can be conducted in our eleven DVL centres.

C17 Developmental Therapeutics Committee

C17 DVL Pre-Clinical Studies

DVL Phase I/II sites

C¹⁷ Developmental Therapeutics Committee

C¹⁷ DVL Pre-Clinical Studies